E
LOGC

Ergoteles’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Ergoteles’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-65,827
Closed -$301K – 1731
2021
Q3 		$301K Sell
65,827
-956
-1% -$4.2K 0.01% 795
2021
Q2 		$297K Buy
+66,783
New +$340K 0.01% 1070

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return

Ergoteles's LOGC Position: Q4 2021 in Review

Ergoteles sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2021, closing a stake of 65,827 shares — an estimated $301K sold.

Ergoteles first reported a position in LOGC in Q2 2021 and held it in 2 quarters. The position peaked at $301K in Q3 2021. 57 funds tracked by Wall St. Rank hold LOGC as of Q4 2021.

  • Ergoteles reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Ergoteles sold 65,827 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $301K.
  • Ergoteles first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Ergoteles's LogicBio Therapeutics, Inc. Common Stock position peaked at $301K in Q3 2021.
  • 57 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.